Your session is about to expire
← Back to Search
Pembrolizumab Combo for Melanoma
Study Summary
This trial is testing experimental treatments for melanoma to see if they are more effective than the current options.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had major surgery within the last 3 weeks.I have a history of hepatitis B.My melanoma diagnosis was confirmed through lab tests.I have an autoimmune disease treated with medication in the last 2 years.I have had serious heart problems in the last year.I have had 3 or fewer treatments for my advanced melanoma.I am a male willing to use contraception if I take lenvatinib or ATRA.My melanoma cannot be removed with surgery and is in stage III or IV.I have an immune system disorder or have been on immune-weakening medication recently.I have not received a live vaccine in the last 30 days.I am not pregnant or breastfeeding, and if I can have children, I use effective birth control or practice abstinence.I have another cancer that is getting worse or needed treatment in the last 2 years.My scans show cancer affecting major blood vessels or has caused holes in the tumor.I have received an organ or tissue transplant from another person.I have had active tuberculosis in the past.You have given a sample of your tumor for testing.I am currently being treated for an infection.I have not had significant coughing up of blood or tumor bleeding in the last 2 weeks.My side effects from the last treatment are mild, except for hair loss.My cancer has grown despite treatment with specific immune therapy.You have been diagnosed with HIV.You have had a serious allergic reaction to a different type of medication in the past.I have not had cancer treatment in the last 4 weeks.My melanoma is in the eye or on mucous membranes.I have a severe fistula.My condition worsened despite treatment with an anti-PD-1/L1 drug.I have had lung inflammation not caused by an infection.My organs are functioning well.My cancer has spread to my brain or spinal cord.I had radiotherapy less than 2 weeks before starting the study treatment.
- Group 1: Pembrolizumab + Quavonlimab + Vibostolimab
- Group 2: Pembrolizumab + Quavonlimab + Lenvatinib
- Group 3: Pembrolizumab + all-trans retinoic acid (ATRA)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are engaged in this medical experiment?
"Merck Sharp & Dohme LLC is sponsoring this clinical trial, which requires 200 qualifying patients to be recruited from two locations: the University of Texas MD Anderson Cancer Centre in Houston, TX and UCLA Hematology & Oncology in Los Angeles, CA."
Do I meet the criteria to partake in this investigation?
"Patients with melanoma aged 18 to 120 years old have the opportunity to be chosen for this clinical trial. Approximately 200 participants are being recruited."
Is the enrollment period still open for this research project?
"Affirmative. The information hosted on clinicaltrials.gov states that this research is currently enlisting patients; it was initially posted in June of 2020, and revised last October. 200 people are being sought to participate at 12 sites across the country."
What medical conditions usually necessitate the administration of Pembrolizumab?
"Pembrolizumab is generally prescribed to patients with unresectable melanoma, yet it has also proved effective in managing microsatellite instability high, the risk of recurrence, and other diseases."
What prior investigations involving Pembrolizumab have been conducted?
"At the moment, 1032 clinical trials exploring pembrolizumab exist. Of those, 134 are currently in Phase 3 of their research process. The primary study centre is located in Sacramento, California; however 37065 other locations are conducting studies using this medication."
Does this research accommodate octogenarians?
"According to the established criteria for this clinical trial, individuals aged 18-120 are eligible for enrollment."
Are there a substantial number of locations administering this study in North America?
"The research team at UT MD Anderson Cancer Center in Houston, Texas; UCLA Hematology & Oncology in Los Angeles, California; NYU Clinical Cancer Centre in New york City and 12 other sites are coordinating this clinical trial."
Share this study with friends
Copy Link
Messenger